Conditional Immortalization of Lymphoid Progenitors via Tetracycline-Regulated LMO2 Expression

Hum Gene Ther. 2020 Feb;31(3-4):183-198. doi: 10.1089/hum.2019.212. Epub 2020 Jan 24.

Abstract

Conditional immortalization of hematopoietic progenitors through lentiviral expression of selected transcription factors in hematopoietic stem and progenitor cells provides a promising tool to study stem cell and leukemia biology. In this study, to generate conditionally immortalized lymphoid progenitor (ciLP) cell lines, murine hematopoietic progenitor cells were transduced with an inducible lentiviral "all-in-one" vector expressing LMO2 under doxycycline (DOX) stimulation and the reverse tetracycline-regulated transactivator (rtTA3). For selection of LMO2-expressing ciLPs (LMO2-ciLPs) and longitudinal manipulation in T cell differentiation lymphoid conditions, we developed a robust approach based on coculture with OP9-DL1 stromal cells and improved cytokine conditions allowing a controlled balance between cell proliferation and differentiation in vitro. LMO2-ciLP cell lines with the highest proliferation, vector copy number, and similar insertion pattern were selected for LMO2 "on/off" in vitro study. LMO2 expression under DOX induction resulted in a double negative (DN) 2 differentiation arrest and a propagation of CD44+CD25- myeloid cell population characterized by lymphoid and myeloid phenotypes, respectively. Both DN2 and CD44+CD25- myeloid cell subpopulations expressed c-KIT, suggesting that LMO2-ciLPs were similar to uncommitted progenitors under DOX supplementation. DOX removal resulted in cessation of ectopic LMO2 expression and LMO2-ciLPs continued T cell lymphoid differentiation accompanied by c-KIT downregulation and interleukin 7 receptor expression. Switching off LMO2 expression was accompanied by increased Notch signaling and significant reduction of the CD44+CD25- myeloid cell population under T cell differentiation lymphoid conditions. Although vector insertions in cooperation with LMO2 expression could influence the fate of LMO2-ciLPs and additional experiments are required to evaluate it, our approach provides a promising tool to investigate mechanisms underlying stem cell, leukemia, and lymphocyte biology, leading to novel approaches for disease modeling and therapy evaluation.

Keywords: LMO2; conditional immortalization; conditionally immortalized lymphoid progenitors; lentiviral “all-in-one” vector; lymphoid progenitor cell lines; tetracycline-regulated.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / genetics*
  • Animals
  • Biomarkers
  • Cell Differentiation / genetics
  • Cell Line
  • Cell Lineage / genetics
  • Cell Transformation, Neoplastic / genetics*
  • Gene Expression Regulation / drug effects*
  • Hematopoietic Stem Cells / metabolism
  • Humans
  • Immunophenotyping
  • LIM Domain Proteins / genetics*
  • Lymphoid Progenitor Cells / metabolism*
  • Lymphoid Progenitor Cells / pathology
  • Mice
  • Mice, Transgenic
  • Plasmids / genetics*
  • Proto-Oncogene Proteins / genetics*
  • Tetracyclines / pharmacology*
  • Transduction, Genetic
  • Transgenes*

Substances

  • Adaptor Proteins, Signal Transducing
  • Biomarkers
  • LIM Domain Proteins
  • LMO2 protein, human
  • Proto-Oncogene Proteins
  • Tetracyclines